Medicare Part D-A Roundtable Discussion of Current Issues and Trends

被引:9
作者
Balfour, Donald C., III [1 ]
Evans, Steven [2 ]
Januska, Jeff [3 ]
Lee, Helen Y. [4 ]
Lewis, Sonya J. [5 ]
Nolan, Steve R. [6 ]
Noga, Mark [7 ]
Stemple, Charles [8 ]
Thapar, Kishan [9 ]
机构
[1] Sharp Rees Stealy Med Grp, San Diego, CA 92101 USA
[2] Hlth Palm Nevada, Las Vegas, NV USA
[3] CenCal Hlth, Serv Pharm, Goleta, CA USA
[4] CareFirst BlueCross Blueshield, Clin Serv, Baltimore, MD USA
[5] Univ Colorado, Sch Pharm, Denver, CO 80202 USA
[6] Rocky Mt Hlth Plans, Fruita, CO USA
[7] Coventry Hlth Care, Harrisburg, PA USA
[8] Humana Healthcare Ohio, Cincinnati, OH USA
[9] ProMed HealthCare Administrators, Ontario, CA USA
来源
JOURNAL OF MANAGED CARE PHARMACY | 2009年 / 15卷 / 01期
关键词
D O I
10.18553/jmcp.2009.15.s1.3
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BACKGROUND: Medicare Part D was introduced with a goal of providing access to prescription drug coverage for all Medicare beneficiaries. Regulatory mandates and the changing landscape of health care require continued evaluation of the state of the Part D benefit. OBJECTIVE: To review the current state of plan offerings and highlight key issues regarding the administration of the Part D benefit. SUMMARY: The Part D drug benefit continues to evolve. The benefit value appears to be diluted compared to the benefit value of large employer plans. Regulatory restrictions mandated by the Centers for Medicare and Medicaid Services (CMS) are reported to inhibit the ability of plans to create an effective, competitive drug benefit for Medicare beneficiaries. Management in this restrictive environment impedes competitive price negotiations and formulary coverage issues continue to create confusion especially for patients with chronic diseases. The doughnut hole coverage gap represents a significant cost-shifting issue for beneficiaries that may impact medication adherence and persistence. To address these and other challenges, CMS is working to improve the quality of care for Part D beneficiaries by designing and supporting demonstration projects. Although these projects are in different stages, all stakeholders are hopeful that they will lead to the development of best practices by plans to help manage their beneficiaries more efficiently. CONCLUSIONS: A significant number of Medicare beneficiaries are currently receiving prescription drug benefits through Part D. The true value of this benefit has been called Into question as a result of plan design parameters that lead to cost-shifting, an Increasing burden for enrollees. Concerns regarding the ability to provide a competitive plan given the stringent rules and regulations have been voiced by plan administrators. In an effort to drive toward evidence-based solutions, CMS is working to improve the overall quality of care through numerous demonstration projects.
引用
收藏
页码:S3 / S9
页数:7
相关论文
共 9 条
  • [1] *CTR MED MED SERV, MED DEM
  • [2] *CTR MED MED SERV, CAR MAN HIGH COST BE
  • [3] *CTR MED MED SERV, EL HLTH REC EHR DEM
  • [4] Medicare Part D: Selected issues for plan sponsors, pharmacists, and beneficiaries in 2008
    DePue, Ronnie
    Stubbings, JoAnn
    [J]. JOURNAL OF MANAGED CARE PHARMACY, 2008, 14 (01): : 50 - 60
  • [5] Hoadley J., MEDICARE PRESCRIPTIO
  • [6] HOIDLEY H, 2007, MEDICARE D
  • [7] Unintended consequences of caps on medicare drug benefits
    Hsu, John
    Price, Mary
    Huang, Jie
    Brand, Richard
    Fung, Vicki
    Hui, Rita
    Fireman, Bruce
    Newhouse, Joseph P.
    Selby, Joseph V.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (22) : 2349 - 2359
  • [8] *PHARM, MED PROGR PROH MIDY
  • [9] Wilk JE, 2008, PSYCHIAT SERV, V59, P34, DOI 10.1176/ps.2008.59.1.34